NCT03890809

An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of BMS-986165 in Participants With Normal Hepatic Function and Participants With Mild, Moderate and Severe Hepatic Impairment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate BMS-986165 in participants with different levels of liver function.

Conditions

• Liver Dysfunction
• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	BMS-986165	Oral administration

Timeline

• Start date: 2019-02-26
• Primary completion: 2019-11-30
• Completion: 2019-11-30
• First posted: 2019-03-26
• Last updated: 2020-08-26

Locations

4 sites across 3 countries: Czechia, Hungary, Slovakia

Regulatory

• FDA-regulated drug study